We inserted the 0.6 mm caliber graft-heparin (in inner wall) conduits into the tailarteries of 14 mice. The results showed that the graft conduit could be used repeatedly with no blood oozing out in the wound, no massive internal hemorrhage, and no additional coagulative reagent given during the whole experiment. On the other hand, the graft-heparin conduits of variant caliber were inserted into the femur arteries of 4 rabbits and 4 dogs for blood pressure experiment and femur arterio-venous bypass tests. The results showed that the anticoagulative effect of these conduits was markedly improved, but there was a strip of thrombus. There was no thrombus track in the wall of the conduit. The strip of thrombus was formed first in the cone of conduit where caliber changed. The results indicate that the blood flow resistance is in inverse proportion to 4 power of the conduit radius. So the thinner the conduit is, the more sensitive to conduit radius variation the conduit resistance will be. In studying and making the arfificial conduit, one must take notice of the conduit caliber, which should be equal to the caliber of the blood vessel.
Animals ; Anticoagulants ; administration & dosage ; Blood Vessel Prosthesis ; Dogs ; Heparin ; administration & dosage ; Mice ; Rabbits ; Regional Blood Flow

Coronary Artery Bypass ; Coronary Occlusion ; diagnosis ; etiology ; Female ; Heparin ; administration & dosage ; therapeutic use ; Humans ; Middle Aged

OBJECTIVES: The effects of ethanol and phenobarbital,which are known to affect metabolism of xenobiotics, on the formation of benzidine-and its metabolites-plasma protein adducts in rats administered benzidine were evaluated. METHODS: The experimental rats were divided into the control,ethanol and phenobar-bital groups. The experimental groups (ethanol and phenobarbital group)were pretreated with ethanol (1g/kg)or phenobarbital (80mg/kg)24 hours prior to the oral administration of benzidine (0.5mmol/kg). Blood samples were obtained from the vena cava from 5 rats in each group; and at 30 min,3 h,6 h,9 h,12 h,24 h,48 h,72 h,96 h,and 144 h after the administration of benzidine using heparin treated syringes.The plasma protein levels were separated immediately after taking blood samples. The adducts were underwent basic hydrolysis to convert them into aromatic amines. The hydrolyzed benzidine, monoacetylbenzidine, and 4-aminobiphenyl were analyzed by reverse-phased liquid chro-matography with an electrochemical detector. The quantitative amount of the metabolites was expressed by the plasma protein binding index(PBI). RESULTS: Similar to the hemoglobin adducts,the levels of the plasma protein adducts of the ethanol and phenobarbital groups (benzidine-, monoacetylbenzidine-, and 4-amino-biphenyl-PBI)were higher than those of the control group. These results are attributable to the fact that ethanol and phenobarbital induced to the plasma protein adduct formation. The N-acetylation ratio in the control group was highest at 72 h with 2.34.In the ethanol group,it was highest at 72 h with a ratio of 2.46 and was highest in the phenobarbital group at 72 h with a ratio of 2.43. The N-acetylation ratio of the plasma protein adducts was relatively lower than that of the hemoglobin adducts.The level of the plasma protein adduct increased more rapidly than the hemoglobin adducts in all experimental groups regardless of the pretreatment,and decreased rapidly after reaching the maximum level. CONCLUSION: The above results indicate that ethanol and phenobarbital increased the level of plasma protein adduct formation. The plasma protein adducts tended to decrease more rapidly than the hemoglobin adducts in the body after benzidine exposure. This results in this study result suggests that the effects of ethanol or phenobarbital need to be considered in the biochemical monitoring,and that the level of the plasma protein adducts be a more proper biomarker than the hemoglobin adducts for assessing the short term exposure to a benzidine and benzidine based dye.
Administration, Oral ; Amines ; Animals ; Environmental Monitoring* ; Ethanol* ; Heparin ; Hydrolysis ; Metabolism ; Phenobarbital* ; Plasma* ; Protein Binding ; Rats* ; Xenobiotics

Extra-luminal flow hollow fiber membrane oxygenator (ELFHFMO) has been widely applied in cardiopulmonary bypass (CPB) and extracorporeal membrane oxygenation (ECMO) or extracorporeal life support (ECLS) because of its advantages over other types of MO. But its low hemocompatibility and durability are the major problems in clinical application that even have limited its wide application. In this paper, we reviewed the recent researches on how to improve the hemocompatibility and durability of ELFHFMO.
Coated Materials, Biocompatible ; Extracorporeal Membrane Oxygenation ; instrumentation ; Heparin ; administration & dosage ; Humans ; Oxygenators, Membrane ; trends

Objective This study was designed to evaluate the efficacy and safety of aspirin-heparin treatment for un-explained recurrent spontaneous abortion (URSA). Methods Literatures reporting the studies on the aspirin-heparin treatment of un-explained recurrent miscarriage with randomized controlled trials (RCTs) were collected from the major publication databases. The live birth rate was used as primary indicator, preterm delivery, preeclampsia, intrauterine growth restriction, and adverse reactions (thrombocytopenia ) were used as the secondary indicators. The quality of the included studies was evaluated using RCT bias risk assessment tool in the Cochrane Handbook (v5.1.0). Meta-analysis was conducted using RevMan (v5.3) software. Subgroup analyses were conducted with an appropriately combined model according to the type of the treatments if heterogeneity among the selected studies was detected. Results Six publications of RCTs were included in this study. There were a total of 907 pregnant women with diagnosis of URSA, 367 of them were pooled in the study group with aspirin-heparin therapy and 540 women in the control group with placebo, aspirin or progesterone therapy. Meta-analysis showed that the live birth rate in the study group was significantly different from that in the control group [RR = 1.18, 95% CI (1.00-1.39), P=0.04]. Considering the clinical heterogeneity among the six studies, subgroup analysis were performed. Live birth rates in the aspirin-heparin treated groups and placebo groups were compared and no significant difference was found. There were no significant differences found between the two groups in the incidence of preterm delivery [RR=1.22, 95% CI (0.54-2.76), P=0.64], preeclampsia [RR=0.52, 95% CI (0.25-1.07), P=0.08], intrauterine growth restriction [RR=1.19, 95% CI (0.56-2.52), P=0.45] and thrombocytopenia [RR=1.17, 95% CI (0.09-14.42), P=0.90]. Conclusion This meta-analysis did not provide evidence that aspirin-heparin therapy had beneficial effect on un-explained recurrent miscarriage in terms of live birth rate, but it was relatively safe for it did not increase incidence of adverse pregnancy and adverse events. More well-designed and stratified double-blind RCT, individual-based meta-analysis regarding aspirin-heparin therapy are needed in future.
Abortion, Habitual ; drug therapy ; Aspirin ; administration & dosage ; adverse effects ; Female ; Heparin ; administration & dosage ; adverse effects ; Humans ; Pregnancy ; Publication Bias

Lipoprotein lipase (LPL) is known to be attached to the luminal surface of vascular endothelial cells in a complex with membrane-bound heparan sulfate, and released into blood stream by heparin. LPL that catalyzes hydrolysis of triglyceride (TGL) on chylomicron and VLDL into two fatty acids and monoacylglycerol, is also implicated to participate in an enhancement of cholesterol uptake by arterial endothelial cells in vitro. But little is known about the LPL-mediated cholesterol uptake in physiological state. In this study, changes in blood lipid composition and levels of lipoproteins were determined after the injection of heparin in human. The level of LPL in plasma was increased from 0 to 11 mU/ml within 30-40 min post-heparin administration and decreased to the basal level within 2 h. The level of TGL in plasma decreased from 70 mg/dl to 20 mg/dl within 1 h and gradually increased to 80 mg/dl within 4 h. However the level of total cholesterol in plasma remained at 140 mg/dl during an experimental period of 4 h. Analysis of Lipoproteins in plasma by NaBr density gradient ultracentrifugation showed that the level of VLDL decreased from 50 mg/dl to 10 mg/dl within 1-2 h and returned to normal plasm level at 4 h. However there were no significant changes in the level of LDL and HDL. These results suggest that, at least, in normo-lipidemic subjects, increased free plasm LPL acts primarily on VLDL and failed to show any significant uptake of cholesterol-rich lipoproteins in human.
Adult ; Cholesterol/blood ; Heparin/pharmacology* ; Heparin/administration & dosage ; Human ; Immunoblotting ; Lipoprotein Lipase/blood* ; Lipoproteins/blood* ; Lipoproteins, HDL/blood ; Lipoproteins, LDL/blood ; Lipoproteins, VLDL/blood ; Triglycerides/blood

Drug-coated stent play an important role in percutaneous transluminal coronary angioplasty (PTCA), and it constitutes an innovation to further reduce the incidence of restenosis. In this paper, the mechanisms and the process of endovascular stent implantation,and the principles of drug release of drug-coated stent are reviewed. Especially, polymer coated design and the further development of drug eluting stents are discussed.
Angioplasty, Balloon, Coronary ; instrumentation ; Coronary Restenosis ; prevention & control ; Drug Delivery Systems ; Drug-Eluting Stents ; Heparin ; administration & dosage ; Humans ; Paclitaxel ; administration & dosage ; Sirolimus ; administration & dosage

Heparin-induced thrombocytopenia (HIT) is a relatively infrequent complication of heparin administration. HIT can cause devastating thrombosis, making it one of the most serious adverse drug reactions encountered in clinical practice. We successfully treated a case of severe HIT presenting with thrombosis and life-threatening bleeding complications with intravenous immunoglobulin (IVIG), platelet transfusion and oral anticoagulant Rivaroxaban. In this case, we considered that IVIG played the most important role by preventing further thrombosis, increasing the platelet count, and ensuring the efficacy of Rivaroxaban. We therefore suggest that IVIG might be the optimal treatment for patients with this urgent condition.
Aged, 80 and over ; Female ; Heparin ; administration & dosage ; adverse effects ; Humans ; Immunoglobulins, Intravenous ; administration & dosage ; Platelet Transfusion ; Rivaroxaban ; administration & dosage ; Thrombocytopenia ; chemically induced ; therapy

Acute cytomegalovirus (CMV) infection occurs commonly in immunocompromised and immunocompetent patients, but is usually asymptomatic in the latter. Vascular events associated with acute CMV infection have been described, but are rare. Hence, such events are rarely reported in the literature. We report a case of pulmonary embolism secondary to acute CMV colitis in an immunocompetent 78-year-old man. The patient presented with fever and diarrhea. Colonic ulcers were diagnosed based on colonoscopy findings, and CMV was the proven etiology on pathological examination. The patient subsequently experienced acute respiratory failure. Pulmonary embolism was diagnosed based on the chest radiography and computed tomography findings. A diagnosis of acute CMV colitis complicated by pulmonary embolism was made. The patient was successfully treated with intravenous administration of unfractionated heparin and intravenous ganciclovir.
Administration, Intravenous ; Aged ; Colitis* ; Colon ; Colonoscopy ; Cytomegalovirus* ; Diagnosis ; Diarrhea ; Fever ; Ganciclovir ; Heparin ; Humans ; Pulmonary Embolism* ; Radiography ; Respiratory Insufficiency ; Thorax ; Ulcer

OBJECTIVETo study the therapeutic effects of early administration of low-dose heparin in patients with severe sepsis.

METHODSTwenty-two patients were randomly divided into experimental group and control group. In addition to the routine treatment, the patients in experimental group were given low-dose heparin, while those in control group were not. Prothrombin time (PT), activated partial thromboplastin time (APTT), platelet count, APACHE II score, ICU days, hospital days, cure rate, and 28-day survival rate were investigated in the two groups.

RESULTSAfter the treatment, PT and APTT recovered normal in the experimental group, but remained abnormal in the control group. There was no significant difference in platelet count between the two groups. ICU days in experimental group was shorter than that in control group (P < 0.01). Cure rate in experimental group was 81.8%, which was significantly higher than that in control group (54.5%). There was no significant difference in hospital days and 28-day survival rate between the two groups.

CONCLUSIONSEarly administration of low-dose heparin therapy can improve coagulative function in patients with severe sepsis, however, the survival rate was not improved.

Aged ; Anticoagulants ; administration & dosage ; Combined Modality Therapy ; Female ; Heparin ; administration & dosage ; Humans ; Injections, Intravenous ; Male ; Middle Aged ; Sepsis ; drug therapy ; mortality ; therapy ; Survival Rate ; Treatment Outcome